This is in contrast to other subtypes of B-cell lymphoma that have strongly increased levels of miR-155 and do not depend on AICDA-driven MYC translocations, but may benefit from the miR-155-mediated suppression of SOCS1 resulting in reduced p53 activity [6-8]. The gene discussed is TP53; the disease is B-cell non-Hodgkin lymphoma.